Ascletis Pharma Inc. has announced the selection of ASC36, its first oral amylin receptor peptide agonist, for clinical development. ASC36 oral tablets were developed using the company's proprietary Peptide Oral Transport ENhancement Technology (POTENT). In non-human primate studies, the tablets achieved an absolute oral bioavailability of 6% to 8% at steady state. Ascletis plans to submit an Investigational New Drug Application $(IND)$ to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026. No clinical study results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021298), on February 10, 2026, and is solely responsible for the information contained therein.